Patent ID: 9213038
Filing Date: 2015-12-15
Classification: A61K,C07K,G01N

Abstract:
1. A method for using an anti-VEGF therapy, without inducing proteinuria, to treat cancer in a human having cancer, wherein said method comprises: (a) administering an initial dose of said anti-VEGF therapy to said human to treat said cancer, (b) obtaining a urine sample from said human receiving said anti-VEGF therapy, (c) contacting said urine sample with an antibody that binds to podocytes or polypeptides expressed by podocytes to form an antigen-antibody complex, if podoycytes or polypeptides expressed by podocytes are present in said sample, (d) detecting, by flow cytometry, the presence of said antigen-antibody complex, thereby identifying said human as being at risk of developing proteinuria, if said complex is detected and (e) administering a subsequent dose of said anti-VEGF therapy to said human who does not have proteinuria, but in whom the antigen-antibody complex has been detected, wherein said subsequent dose is at least 30 percent lower than said initial dose.